This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Zosano Pharma Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

-5.0%

Tasa de crecimiento de los beneficios

75.3%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	4.3%
Tasa de crecimiento de los ingresos	86.7%
Rentabilidad financiera	-392.7%
Margen neto	-8,375.1%
Última actualización de beneficios	31 Mar 2022

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos

Cómo gana y gasta dinero Zosano Pharma. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

DB:0ZP Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Mar 22	1	-55	11
31 Dec 21	1	-30	11
30 Sep 21	1	-31	11
30 Jun 21	1	-31	11
31 Mar 21	0	-33	11
31 Dec 20	0	-33	11
30 Sep 20	0	-34	12
30 Jun 20	0	-35	12
31 Mar 20	0	-37	12
31 Dec 19	0	-38	12
30 Sep 19	0	-39	11
30 Jun 19	0	-37	10
31 Mar 19	0	-37	10
31 Dec 18	0	-35	9
30 Sep 18	0	-33	9
30 Jun 18	0	-32	8
31 Mar 18	0	-30	8
31 Dec 17	0	-29	8
30 Sep 17	0	-29	8
30 Jun 17	0	-29	8
31 Mar 17	0	-29	8
31 Dec 16	0	-30	8
30 Sep 16	0	-30	8
30 Jun 16	0	-31	7
31 Mar 16	0	-32	7
31 Dec 15	0	-28	6

Ingresos de calidad: 0ZP is currently unprofitable.

Margen de beneficios creciente: 0ZP is currently unprofitable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: 0ZP is unprofitable, and losses have increased over the past 5 years at a rate of 5% per year.

Acelerando crecimiento: Unable to compare 0ZP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Beneficios vs. Industria: 0ZP is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-37.9%).

Rentabilidad financiera

Alta ROE: 0ZP has a negative Return on Equity (-392.74%), as it is currently unprofitable.

This company is no longer active

Zosano Pharma Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2022 earnings released: US$7.87 loss per share (vs US$2.73 loss in 1Q 2021)

Zosano Pharma Corporation Reports Impairment Charges for the First Quarter Ended March 31, 2022

Recent updates

Emergex USA Corporation completed the acquisition of Substantially all assets of Zosano Pharma Corporation for $1 million.

Emergex USA Corp. agreed to acquire Substantially all assets of Zosano Pharma Corporation (OTCPK:ZSAN.Q) for $1.3 million.

Motion for Case Conversion Filed for Zosano Pharma Corporation

Motion for Asset Sale Filed by Zosano Pharma Corporation

Zosano Pharma Corporation to Delist from Nasdaq

Zosano Pharma Corporation Filed for Bankruptcy

First quarter 2022 earnings released: US$7.87 loss per share (vs US$2.73 loss in 1Q 2021)

Joseph “Jay” P. Hagan Resigns as Director of the Board of Directors of Zosano Pharma Corporation

Zosano Pharma Corporation Reports Impairment Charges for the First Quarter Ended March 31, 2022

Steven A. Elms Tenders His Resignation as Director of the Board of Directors of Zosano Pharma Corporation

Zosano Pharma Corporation Receives a Response Letter from the U.S. Food and Drug Administration with Regard to the Company’s January 18, 2022 Resubmission of the 505(b)(2) New Drug Application for M207

Zosano Pharma Corporation has completed a Composite Units Offering in the amount of $15.375 million.

Zosano Pharma Corporation has completed a Composite Units Offering.

Zosano Pharma Corporation Resubmits its M207 (Zolmitriptan Transdermal Microneedle System) 505(B)(2) New Drug Application to the U.S. Food and Drug Administration

Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of A Trivalent Influenza Vaccine Formulated on Its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine At A Higher Dose

Zosano Pharma Corporation Announces Publication of Clinical Data Regarding the Long-Term Use of Qtrypta for the Treatment of Acute Migraine in the Journal of Headache and Pain

Zosano Pharma Confirms Plan to Move Forward with Pharmacokinetic Study Following Protocol Review by FDA

Revenue in line with expectations

Zosano Pharma Corporation Announces John Walker, Chairman of the Board of Directors to Retire from the Board

Zosano Pharma Confirms NDA Resubmission Strategy Following Type A Meeting Minutes from FDA

New 90-day high: €1.26

Zosano Pharma Corporation Announces NDA Resubmission Plans Following Type A Meeting with FDA

New 90-day high: €0.90

New 90-day high: €0.64

Zosano Pharma Requests Type A Meeting with the Fda to Review Resubmission Plans for Qtrypta™ New Drug Application

Bragar Eagel & Squire, P.C. Reminds Investors of Class Action Lawsuit Filed Against Zosano Pharma Corporation

Pomerantz LLP Reminds Shareholders with Losses on Their Investment in Zosano Pharma Corporation of Class Action Lawsuit and Upcoming Deadline

New 90-day low: €0.21

Rosen Announces Filing of Securities Class Action Lawsuit Against Zosano Pharma Corporation

New 90-day low: €0.54

New 90-day low: €0.64

Zosano Pharma Corporation Receives Discipline Review Letter from the U.S. Food and Drug Administration in Connection with the Qtrypta

Zosano Pharma Corporation has completed a Follow-on Equity Offering in the amount of $20.782018 million.

New 90-day high - €1.11

Zosano Pharma Corporation(NasdaqCM:ZSAN) dropped from Russell Microcap Growth Index

Desglose de ingresos y gastos

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado